Analysis of Revenues
Paying user area
Try for free
Johnson & Johnson pages available for free this week:
- Balance Sheet: Liabilities and Stockholders’ Equity
- Cash Flow Statement
- Common-Size Balance Sheet: Assets
- Analysis of Solvency Ratios
- Analysis of Short-term (Operating) Activity Ratios
- Present Value of Free Cash Flow to Equity (FCFE)
- Return on Equity (ROE) since 2005
- Return on Assets (ROA) since 2005
- Debt to Equity since 2005
- Price to Book Value (P/BV) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Johnson & Johnson for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Revenues as Reported
Johnson & Johnson, income statement, revenues
US$ in millions
| 12 months ended: | Dec 28, 2025 | Dec 29, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Innovative Medicine | |||||||||||
| MedTech | |||||||||||
| Sales to customers |
Based on: 10-K (reporting date: 2025-12-28), 10-K (reporting date: 2024-12-29), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
Overall revenue performance demonstrates varied trends across different segments between 2021 and 2025. While total sales to customers initially experienced modest growth, a subsequent decline was observed before recovering towards the end of the analyzed period. A detailed examination of individual segments reveals differing performance characteristics.
- Innovative Medicine
- Revenue from Innovative Medicine exhibited a slight increase from US$66,715 million in 2021 to US$67,516 million in 2022. However, a significant decrease occurred in 2023, with revenue falling to US$54,759 million. A partial recovery was noted in 2024, reaching US$56,964 million, followed by further growth to US$60,401 million in 2025. This segment demonstrates volatility, with a clear dip in 2023 followed by a recovery, but not returning to initial levels.
- MedTech
- MedTech revenue showed consistent growth throughout the analyzed period. Starting at US$27,060 million in 2021, it increased to US$27,427 million in 2022, US$30,400 million in 2023, US$31,857 million in 2024, and reached US$33,792 million in 2025. This segment consistently contributed to overall revenue and demonstrated a positive growth trajectory.
- Sales to Customers (Total)
- Total sales to customers increased marginally from US$93,775 million in 2021 to US$94,943 million in 2022. A notable decline was observed in 2023, with revenue decreasing to US$85,159 million. A recovery began in 2024, with sales reaching US$88,821 million, and continued into 2025, achieving US$94,193 million. The 2025 figure represents a return to levels comparable to those observed in 2021 and 2022, indicating a rebound after the 2023 downturn.
The decline in overall sales in 2023 appears to be primarily driven by a reduction in Innovative Medicine revenue. While MedTech consistently grew, it was insufficient to offset the decrease in the other segment. The recovery observed in 2024 and 2025 suggests a stabilization of the Innovative Medicine segment and continued strength in MedTech, leading to a return to near-prior peak sales levels.